Publications
Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer chemotherapy and pharmacology. 2010. PMID: 20130876
Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or int Haematologica. 2010. PMID: 20139391
Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. PMID: 20124187
Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Science translational medicine. 2010. PMID: 20371474
Small EJ, Fong L. Developing immunotherapy as legitimate therapy for patients with prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. PMID: 20100956
Small EJ, Fong L. Developing immunotherapy as legitimate therapy for patients with prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. PMID: 20100956
Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010. PMID: 20068102
Soon CW, Algazi AP, Cha EN, Daud AI. New horizons in melanoma treatment: targeting molecular pathways. The Ochsner journal. 2010. PMID: 21603363
Rebecca L. Olin, Dan T. Vogl, Edward A. Stadtmauer. Allogeneic Transplantation for the Treatment of Multiple Myeloma. Allogeneic Stem Cell Transplantation. 2010. PMID:
Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? The oncologist. 2010. PMID: 21115580
Martin SA, Hewish M, Lord CJ, Ashworth A. Genomic instability and the selection of treatments for cancer. The Journal of pathology. 2010. PMID: 19890832
Engstrom PF, Arnoletti JP, Benson AB, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C, NCCN. NCCN clinical practice guidelines in oncology. Anal carcinoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2010. PMID: 20064293
Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. The oncologist. 2010. PMID: 21115576
Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology. American Society of Hematology. Education Program. 2010. PMID: 21239786
Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology. American Society of Hematology. Education Program. 2010. PMID: 21239786
Shah S, Small E. Emerging biological observations in prostate cancer. Expert review of anticancer therapy. 2010. PMID: 20014889
Armstrong EJ, Bhave P, Wong D, Ursell PC, Kaplan L, Yeghiazarians Y, Ai WZ. Left ventricular rupture due to HIV-associated T-cell lymphoma. Texas Heart Institute journal. 2010. PMID: 20844622
Barok M, Balazs M, Lazar V, Rakosy Z, Toth E, Treszl A, Vereb G, Colbern GT, Park JW, Szollosi J. Characterization of a novel, trastuzumab resistant human breast cancer cell line. Frontiers in bioscience (Elite edition). 2010. PMID: 20036907
Kim TK, Billard MJ, Wieder ED, McIntyre BW, Komanduri KV. Co-engagement of alpha(4)beta(1) integrin (VLA-4) and CD4 or CD8 is necessary to induce maximal Erk1/2 phosphorylation and cytokine production in human T cells. Human immunology. 2010. PMID: 19815047
Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! Journal of cellular physiology. 2010. PMID: 19798694